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The atypical antipsychotic drug clozapine remains one of most effective treatments for schizophrenia,
given a lack of extrapyramidal side effects, improvements in negative symptoms, cognitive impairment,
and in symptoms in treatment-resistant schizophrenia. The adverse effects of clozapine, including
agranulocytosis, make ﬁnding a safe clozapine-like a drug a goal for drug developers. The drug discrimination paradigm is a model of interoceptive stimulus that has been used in an effort to screen
experimental drugs for clozapine-like atypical antipsychotic effects. The present study was conducted to
elucidate the receptor-mediated stimulus properties that form this clozapine discriminative cue by
testing selective receptor ligands in rats trained to discriminate a 1.25 mg/kg dose of clozapine from
vehicle in a two choice drug discrimination task. Full substitution occurred with the 5-HT2A inverse
agonist M100907 and the two preferential D4/5-HT2/α1 receptor antagonists Lu 37-114 ((S)-1-(3-(2-(4(1H-indol-5-yl)piperazin-1-yl)ethyl)indolin-1-yl)ethan-1-one) and Lu 37-254 (1-(3-(4-(1H-indol-5-yl)
piperazin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one). Partial substitution occurred with the D4 receptor antagonist Lu 38-012 and the α1 adrenoceptor antagonist prazosin. Drugs selective for 5-HT2C,
5-HT6 muscarinic, histamine H1, and benzodiazepine receptors did not substitute for clozapine. The
present ﬁndings suggest that 5-HT2A inverse agonism and D4 receptor antagonism mediate the discriminative stimulus properties of 1.25 mg/kg clozapine in rats, and further conﬁrm that clozapine
produces a complex compound discriminative stimulus.
& 2016 Elsevier B.V. All rights reserved.
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1. Introduction
Clozapine (CLZ) is the prototype for atypical antipsychotic
drugs (APDs) (also referred to as second generation APDs) based
upon a negligible risk for extrapyramidal side effects (Matz et al.
1974), a lack of hyperprolactinemia (Meltzer and Fang, 1976;
Meltzer et al. 1989a), an efﬁcacy for negative symptoms (Molina
et al., 2005), improvements in cognitive functioning (Meltzer and
McGurk, 1999; Potkin et al. 2001), an ability to treat suicidality in
schizophrenic patients (Meltzer, 1999), and an improvement in
positive symptoms in treatment-resistant schizophrenia (Kane
et al. 1988). Unfortunately, CLZ produces agranulocytosis in approximately 1% of patients (De Fazio et al. 2015; Idanpaan-Heikkila
et al. 1977), and while these effects are considered uncommon (De
n
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Fazio et al. 2015), the severity of this condition has limited CLZ to
an APD of last resort. Yet, due to the therapeutic efﬁcacy and lack
of extrapyramidal side effects by CLZ, drug development efforts
continue with the goal of developing a safe CLZ-like atypical APD.
One method used to understand the behavioral stimulus
properties of drugs is the drug discriminative paradigm. Drug
discrimination allows researchers to identify the receptor-mediated stimulus properties of psychoactive drugs. The paradigm informs researchers about behaviorally relevant receptor actions and
can be used as a screening tool for identifying compounds with
similar neuro-behavioral pharmacological actions. The effects of a
drug that subjects have been trained to discriminate from noticeably different effects, normally the drug's physiologically inert
vehicle, serves as a discriminative stimulus, or cue, that can be
evaluated by tests to determine if substitution for the cue occurs
with other compounds.
The discriminative stimulus properties of CLZ have been established using this paradigm, with substitution for CLZ occurring
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with many other atypical APDs (Porter and Prus, 2009). Traditionally, drug discrimination studies with CLZ have used a training
dose of 5.0 mg/kg. This dose produces in vivo D2 receptor occupancy equivalent to that found by clinically-effective doses in
humans, suggesting that this dose has clinical relevance (Kapur
et al. 2003). In rats using a 5.0 mg/kg training dose of CLZ, full
substitution (i.e., Z80% CLZ-appropriate responding) has occurred
with the atypical APDs olanzapine (Millan et al. 1999; Moore et al.
1992; Philibin et al. 2005; Prus et al. 2005a), quetiapine (Millan
et al. 1999; Prus et al. 2005b) and melperone (Prus et al. 2004).
Typical APDs (e.g., haloperidol, chlorpromazine; also known as
ﬁrst generation APDs) do not substitute for a 5.0 mg/kg CLZ
training dose (Prus et al. 2004; Prus et al. 2005b). Full generalization does not occur from a 5.0 mg/kg CLZ training dose to all
atypical APDs, however, including sertindole (Prus et al. 2005b),
risperidone (Prus et al. 2005b), ziprasidone (Millan et al. 1999;
although see Prus et al. 2005b), and zotepine (Goudie et al. 2004).
Thus, less than half of atypical APDs tested in rats have produced
full substitution for the traditional 5.0 mg/kg CLZ training dose in
rats.
As is well known in the drug discrimination literature, the
training dose of the training drug is an important variable and
sensitivity to the discriminative stimulus properties of the training
drug is usually increased as the dose of the training drug is reduced, which is indicated by leftward shifts in the generalization
curve and a lower ED50 value (Stolerman et al. 2011). Consistent
with these general ﬁndings, studies using lower training doses of
CLZ in rats have found that the discriminative cue generalizes to
more atypical antipsychotic drugs than higher training doses.
Porter et al. (2000) found full substitution for a 1.25 mg/kg training
dose of CLZ with the atypical APDs risperidone and sertindole. Full
substitution also occurred to olanzapine, although partial substitution (i.e., Z60% CLZ-appropriate responding) occurred with
quetiapine. In other low dose CLZ studies, full substitution also
occurred with atypical APDs melperone (Prus et al. 2004) and
zotepine (Goudie et al. 2004). To further study differences between these training doses in this paradigm, Prus et al. (2005a)
trained rats to discriminate a 1.25 mg/kg dose versus a 5.0 mg/kg
dose versus vehicle in a three choice drug discrimination task. In
this study too, both quetiapine and sertindole induced full substitution for the 1.25 mg/kg CLZ discriminative stimulus, while
risperidone partial substitution for this dose.
The pharmacological mechanisms that differentially mediate
1.25 mg/kg and 5.0 mg/kg CLZ training doses in rats are poorly
understood. Most generalization testing with selective receptor
ligands have been primarily conducted in 5.0 mg/kg CLZ-trained
rats. The results from these investigations suggest that the 5.0 mg/
kg CLZ training dose is mediated primarily by muscarinic receptor
antagonism, based on full stimulus generalization occurring to
muscarinic receptor antagonists (Goudie et al. 1998; Kelley and
Porter, 1997). Thus, muscarinic receptor antagonism may explain
the full stimulus generalization that has occurred from the 5.0 mg/
kg CLZ training dose to atypical APDs with moderate to high afﬁnities for muscarinic receptors, such as olanzapine and quetiapine (Schotte et al. 1996), while full stimulus generalization has
not occurred to atypical APDs with a weak afﬁnity for muscarinic
receptors, such as melperone and ziprasidone (Bolden et al. 1992;
Schotte et al. 1996).
The present study was conducted to characterize the receptormediated stimulus properties of a 1.25 mg/kg CLZ discriminative
stimulus in rats. Ligands selective for dopamine, 5-HT, muscarinic,
noradrenergic, and histaminergic receptors were tested for stimulus generalization in these animals given that CLZ binds with
an appreciable afﬁnity for these receptors (Arnt and Skarsfeldt,
1998; Schotte et al. 1996). In addition, three putative new antipsychotics were included in the study and two of those
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compounds were multitarget compounds interacting with D4/5HT2/α1 receptors that have been speculated to support the clinical
efﬁcacy of CLZ (Brunello et al. 1995; Meltzer, 2007).

2. Results
2.1. Binding afﬁnities
The binding afﬁnities for Lu 37-254 , Lu 37-114, and Lu 35-138
for selected receptors with potential relevance to clozapine's mechanism of action are listed in Table 1 and are expressed as Ki or
IC50. In general, these compounds had relatively similar binding
afﬁnities at the receptors investigated, although there are some
notable differences. Each compound had low nanomolar afﬁnities
at the dopamine D4 receptor, and somewhat lower afﬁnities at the
dopamine D2 receptor, ranging from 75 (Lu-35-138) to 228 nM (Lu
37-254). Lu 37-254 and Lu 37-114 had low nanomolar afﬁnity for
the 5-HT2 receptor, while Lu 35–138 had lower afﬁnity for this
target in the range of 260 nM. Lu 35-138 and Lu 37-254 had low
afﬁnity for the 5-HT2C receptor at 520, and 1200 nM respectively,
while Lu 37-114's afﬁnity for this target was approximately 90 nM.
Each of these three compounds has moderately strong afﬁnities at
the α1 adrenergic receptor, ranging from 6.3 nM in the case of Lu
37-114 to 45 nM for Lu 35-138. Finally, Lu 37-254 and Lu 37-114
have low (1900 nM) to moderate (75 nM) afﬁnities for the 5-HT
transporter, respectively, while Lu 35-138 has low nanomolar afﬁnity for this target. In summary, the rank order (from highest
afﬁnity to lowest afﬁnity) for these compounds is as follows: Lu
37-254, D4 4 5-HT2 4 α1 4D2 c 5-HT2C; Lu 37-114, D4 45HT2 4 α1 45-HT2C 4D2; Lu 35-138, D4 4 α1 4D2 45-HT2 45HT2C. For the 5-HT transporter, Lu-35-138 had the highest afﬁnity
followed by Lu-37-114, which had a moderate afﬁnity; Lu-37-254
had a low afﬁnity for the transporter.
2.2. Drugs that produced full substitution for clozapine
2.2.1. Clozapine
The results of substitution testing with the atypical APD CLZ are
shown in Fig. 1 (left panels). CLZ produced fully generalized for
itself at the training dose (99.0% 7 SEM ¼0.37; ED50 ¼0.20 mg/kg,
95% conﬁdence interval [C.I.] ¼0.16–0.26 mg/kg), 2.5 mg/kg (98.3%
7SEM ¼0.62) and at a 5.0 mg/kg dose (93.0% 72.98). A signiﬁcant
decrease in response rates was observed at the 5.0 mg/kg dose (F
(6, 186) ¼19.93, P o0.0001).
2.2.2. Clozapine time course
Substitution testing and response rate results for the CLZ
training dose (1.25 mg/kg) across different time points are shown
in Fig. 1 (right panels). Again the pretreatment time used for CLZ
training sessions was 60 min. The 1.25 mg/kg CLZ training dose
Table 1
Pharmacological proﬁle of Lu 37-254, Lu 37-114, and Lu 35-138 at selected dopaminergic, serotonergic, and adrenergic receptor targets. Afﬁnity data are presented
as Ki, except where noted otherwise.
Compound

Target (Ki; nM)
D4.2

D2
Lu 37-254
Lu 37-114
Lu 35-138
a
b
c

a

228
120
753b

a

2.6
2.5
5.0c

IC50 (nM)
5-HT2
a

13
4.0
260c

5-HT2C
1200
91
520c

a

α1

5-HT uptake
a

29
6.3
45c

Data presented in this cell is an IC50 value.
Data originally published in Bang-Andersen et al. (2002).
Data originally published in Hertel et al. (2007).

1900
75
3.2c
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Fig. 1. Left: Substitution testing with the atypical APD CLZ. The top panel shows percent CLZ-lever responding and the bottom panel shows response per minute for each
dose tested in male Sprague Dawley rats (N¼ 32) trained to discriminate a 1.25 mg/kg dose of CLZ (60 min prior to session) from vehicle in a two-choice drug discrimination
task. Right: The training dose of CLZ was tested at different pretreatment times prior to a test session and assessed for percent CLZ-lever responding (top panel) and
responses per minute (bottom panel) (N¼8). The ﬁgures include a test with the CLZ training dose (noted as CLZ on the left of the abscissa) and vehicle (noted as VEH on the
abscissa) Data are displayed as means ( 7 SEM). Rats not meeting the response rate minimum were excluded from calculation for percent drug lever responding but were
included in the response rate calculation. N refers to the number of rats tested and included in the analysis unless noted otherwise in parentheses. **P o 0.01 compared to
VEH.

administered 30 min (81.6% 7SEM ¼11.8) and 60 min (99.0%
7SEM ¼0.3) prior to testing produced full generalization from the
CLZ training dose. However, the 0 min, 120 min, and 240 min presession response rates did not differ signiﬁcantly across the different time points (P 40.05).
2.2.3. M100907
The 5-HT2A receptor inverse agonist M100907 (Fig. 2, left panels) produced full substitution for CLZ at the 1.0 mg/kg dose
(85.6% 7SEM ¼10.95; ED50 ¼ 0.04 mg/kg, 95% C.I. ¼0.01–0.14 mg/
kg). Response rates did not differ signiﬁcantly across the doses
tested.
2.2.4. Lu-37-114
The D4/5-HT2/α1 receptor antagonist Lu-37-114 (Fig. 2, middle
panels) also produced full substitution, for the 10.0 mg/kg dose
(98.1%) (7 SEM ¼0.95; ED50 ¼0.24 mg/kg, 95% C.I. ¼ 0.004–13.031).
A small, but signiﬁcant decrease in response rates was observed (F
(7,70) ¼3.60, Po0.01) at the 5.0 mg/kg dose but not at the
10.0 mg/kg dose.

2.2.5. Lu 37-254
The D4/5-HT2/α1 receptor antagonist Lu 37-254 (Fig. 2, right
panels) produced full substitution at the 2.5 mg/kg dose (81.3%
7SEM ¼11.56; ED50 ¼0.92 mg/kg, 95% C.I. ¼0.37–2.27 mg/kg) and
partial substitution at the 1.25 mg/kg (61.6% 7SEM ¼18.01) and
5.0 mg/kg dose (69.3% 7SEM ¼ 15.15). The 5.0 mg/kg dose also
produced a signiﬁcant decrease in response rates (F(5,35)¼ 5.11,
Po0.01).
2.3. Drugs that did not produce full stimulus generalization
The results of substitution testing with all other compounds are
shown in Table 2. All compounds were tested up to doses that
produced a signiﬁcant decrease in response rates relative to vehicle control (Po 0.05), except for ORG 38,457, chlordiazepoxide,
Lu 38-012, Lu 35-138, SB-271,046, and RO 8554. Doses that produced signiﬁcant differences in response rates relative to vehicle
also are indicated in Table 2. The α1 adrenoceptor antagonist
prazosin produced partial substitution for CLZ at the 2.0 mg/kg
dose (68.8% 7SEM ¼ 17.3), and the D4 receptor antagonist Lu 38012 also produced partial substitution at the 5.0 mg/kg dose

A.J. Prus et al. / Brain Research 1648 (2016) 298–305

301

Fig. 2. Substitution testing with the 5-HT2A receptor inverse agonist M100907 (left), the D4/5-HT2/α1 receptor antagonist Lu 37-114 (middle), and the D4/5-HT2/α1 receptor
antagonist Lu 37-254. See Fig. 1 for other details. **Po 0.01 compared to VEH.

(60.9% 7SEM ¼ 12.9). No other compounds listed in this table
produced partial substitution for clozapine.

3. Discussion
The present study evaluated a series of selective receptor ligands as well as ligands with multiple actions for the purpose of
elucidating the discriminative stimulus properties of a 1.25 mg/kg
CLZ training dose in rats. As noted in the introduction, the 1.25 mg/
kg training dose screens atypical and from typical APDs more effectively. CLZ produced full stimulus generalization to itself up to a
5.0 mg/kg training dose, and the discriminative stimulus effects of
the training dose are evident from 30 to 60 min post injection. Full
stimulus generalization occurred from CLZ to only a limited
number of ligands, including th selective 5-HT2A receptor inverse
agonist M100907 and the D4/5-HT2/α1 preferring receptor antagonists Lu 37-114 and Lu 37-254. Beyond this, partial stimulus
generalization occurred to the D4 receptor antagonist Lu 38-012
and α1 adrenoceptor antagonist prazosin.
As noted earlier, CLZ binds to a multitude of receptors, each of
which has at one time or another been investigated as a potential
mediator of atypical antipsychotic actions (Meltzer, 2002). Among
these receptor actions, antagonism of 5-HT2 receptors appears to
be an important component that is shared by nearly every atypical
antipsychotic drug on the market. A receptor binding proﬁle that
includes preferential antagonism of 5-HT2A receptors over D2 receptor remains the most consistent and reliable proﬁle for developing an atypical antipsychotic drug (Meltzer and Massey, 2011;
Meltzer et al. 1989b; Schotte et al. 1996). Amisulpride remains one
of the only atypical APDs lacking an afﬁnity for 5-HT2A receptors
(Abbas et al. 2009).
The present study found full substitution by a 1.0 mg/kg dose of
M100907, which is supportive of 5-HT2A receptor inverse agonism
mediating these stimulus effects. The current study did not ﬁnd,

however, partial or full substitution by the 5-HT2A/2B/2C receptor
antagonist ritanserin. In other studies, the M100907 was found to
produce full substitution for a 1.25 mg/kg CLZ dose in individual
rats (Prus et al. 2004), and full substitution for a M100907 discriminative stimulus occurred with CLZ in rats (Dekeyne et al.
2003). The dose of M100907 that produced full substitution for
CLZ in the present study was higher than a dose of M100907
(0.01 mg/kg) found sufﬁcient to completely block the discriminative stimulus effects of the 5-HT2A/2C receptor agonist (2,5dimethoxy-4-iodohenyl) 2-aminopropan (DOI) (Schreiber et al.
1994). These past ﬁndings suggest that the receptor mechanisms
mediating the stimulus effects of M100907 for the doses used in
the present study may involve more than 5-HT2A receptors, since
M100907 exhibits a moderate afﬁnity for 5-HT2C receptors and α1
adrenoceptors (Pehek et al. 2006). Coinciding with this, Philibin
et al. (2009) reported that both M100907 and α1 adrenoceptor
antagonist prazosin substituted for a CLZ discriminative cue in
male C57BL/6 mice.
Full substitution occurred with the D4/5-HT2/α1 receptor antagonists Lu 37-114 and Lu 37-254 in the present study. As noted
earlier partial substitution occurred with the selective D4 receptor
antagonist Lu 38-012 and the α1 adrenoceptor antagonist prazosin.
Substitution did not occur to the 5-HT2C receptor antagonist
ORG38457. Taking these ﬁndings together, D4 receptor antagonism
may represent part of the clozapine discriminative cue, which has
long been considered a compound stimulus (Goudie et al. 1998).
Given that Lu 37-114 and Lu 37-254 also bind to 5-HT2 and α1
receptors, the additional antagonism of these receptors may have
established stimulus properties more similar to those produced by
CLZ than established by either action alone. No substitution occurred for Lu 35-138, which also is an antagonist for D4 receptors
and α1 adrenoceptors, but this compound also inhibits 5-HT reuptake (Hertel et al. 2007). Enhanced 5-HT concentrations produced by Lu 35-138 may run counter to clozapine's pharmacological proﬁle by activating, rather than blocking, 5-HT2 receptors.
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Table 2
Drugs that did not produce full substitution for CLZ.

Table 2 (continued )
Drug (type)

Drug (type)

Dose

Dopamine Compounds
Haloperidol (typi- Vehicle
cal anti0.05
psychotic drug
0.1
and D2-receptor 0.2
preferring
antagonist)
Lu 38-012 (D4
Vehicle
antagonist)
0.3125
0.625
1.25
2.5
5.0
10.0
Lu 35-138 (D4/α1
Vehicle
5.0
antagonist and
10.0
5-HT reuptake
20.0
inhibitor)
d-Amphetamine
Vehicle
(D2 agonist)
0.25
0.5
1.0
2.0

Number of
Subjects tested (no.
responding)

14
14
14
14

9
12
12
12
12
12
11
5
5
5
4
17
17
16
14
9

(12)

(14)
(9)
(1)

Percent clozapine lever
responding
(SEM)

Dose

Number of
Subjects tested (no.
responding)

Percent clozapine lever
responding
(SEM)

Responses
per minute
(SEM)

10.0
20.0
40.0

10
10
5

32.8
10.4
32.1

(14.5)
(9.9)
(20.0)

76.3
72.6
23.8

(7.7)
(8.9)
(14.9)**

9
10
9
10
10
8

0.5
21.3
24.3
34.1
21.9
40.9

(0.3)
(12.3)
(13.3)
(14.7)
(13.0)
(16.4)

81.1
102.0
91.5
100.0
88.7
83.2

(9.6)
(13.4)
(17.9)
(15.1)
(14.0)
(10.5)

Responses
per minute
(SEM)

0.7
4.1
16.6
24.4

(0.2)
(1.1)
(5.0)
(5.8)

93.6
86.7
61.5
7.9

(8.4)
(10.3)
(7.4)**
(1.2)**

9.1
20.6
23.9
20.1
24.8
60.9
23.4
0.5
5.0
6.2
5.3
0.7
3.0
14.5
11.1
1.0

(8.5)
(11.0)
(12.5)
(10.9)
(12.5)
(12.9)
(12.0)
(0.2)
(3.9)
(4.5)
(4.4)
(0.4)
(2.7)
(8.7)
(8.1)

77.6
89.9
86.5
77.5
74.2
75.4
77.3
65.4
59.1
53.9
49.9
71.6
68.1
61.6
38.0
1.9

(11.4)
(7.4)
(11.7)
(10.0)
(7.9)
(8.7)
(10.6)
(9.3)
(14.6)
(6.0)
(12.7)
(6.6)
(7.1)
(10.1)
(11.6)
(1.1)**

Serotonin compounds
Vehicle
Ritanserin (50.5
HT2A/2B/2C
1.0
antagonist)
2.0
4.0
8.0
16.0
ORG 38,457 (5Vehicle
HT2C antagonist) 1.25
2.5
5.0
10.0
SB-271,046 (5-HT6 Vehicle
antagonist)
1.25
2.5
5
10
RO 8554 (5-HT6
Vehicle
antagonist)
1.0
3.0
10.0
SB-258,741 (5-HT7 Vehicle
1.25
partial inverse
2.5
agonist)
5.0
10.0

20
7
20
20
20
6
3
7
7
7
6
6
12
12
12
12
11
7
7
7
7
10
10
10
10
9

0.6
27.6
8.8
29.8
44.1
49.9
0.0
0.0
0.5
28.1
0.1
16.4
8.5
18.1
30.3
9.1
9.6
0.3
28.8
1.6
6.3
0.6
18.8
10.4
9.2
12.4

(0.7)
(12.1)
(12.6)
(11.1)
(16.4)
(17.2)
(0.0)
(0.0)
(0.5)
(18.1)
(0.0)
(15.1)
(7.1)
(10.9)
(12.5)
(6.5)
(8.7)
(0.1)
(18.3)
(0.7)
(6.1)
(0.3)
(11.9)
(9.8)
(8.9)
(10.4)

97.0
62.1
88.8
93.2
88.7
66.5
18.2
91.9
85.4
78.8
93.9
80.2
85.6
90.2
82.2
74.8
67.5
65.7
67.9
60.4
53.2
83.7
94.3
90.0
89.5
60.6

(10.7)
(10.8)
(10.5)
(10.1)
(11.4)
(14.4)*
(8.9)**
(12.1)
(10.9)
(15.9)
(9.5)
(14.5)
(11.8)
(9.2)
(10.5)
(10.7)
(9.7)
(11.4)
(7.3)
(9.6)
(9.0)
(12.3)
(11.7)
(11.6)
(10.5)
(13.4)*

Noradrenergic compounds
Prazosin (α1
Vehicle
antagonist)
0.125
0.25
0.5
1.0
2.0

9
10
5
10
5
7

2.1
11.3
18.5
54.6
56.8
68.8

(2.0)
(9.7)
(9.9)
(12.6)
(22.1)
(17.3)

102.9
79.9
52.9
76.2
48.2
53.6

(12.1)
(9.7)
(13.9)
(11.7)
(10.5)*
(13.3)**

Muscarinic compounds
Vehicle
Scopolamine
0.03125
(muscarinic
0.125
antagonist)
0.05
Vehicle
Trihexyphenidyl
(M1 muscarinic 0.75
3.0
antagonist)
6.0
12.0

21
22
21
20
13
14
14
14
11

4.9
28.6
33.3
39.2
1.0
23.0
47.5
47.9
48.6

(2.6)
(8.9)
(9.3)
(8.4)
(0.5)
(8.7)
(12.1)
(10.7)
(10.0)

82.9
87.2
76.1
45.9
100.7
110.5
114.6
91.0
53.3

(7.8)
(6.3)
(7.2)**
(6.7)**
(10.3)
(8.7)
(9.4)
(9.3)
(8.1)**

Histamine compounds
Pyrilamine (H1
Vehicle
antagonist)
5.0

10
10

1.0
18.3

(0.5)
(9.8)

72.1
68.9

(7.8)
(8.9)

Anxiolytic compounds
Chlordiazepoxide
Vehicle
(anxiolytic)
1.25
2.5
5.0
10.0
20.0
**
*

P o 0.01.
P o0.05 compared to vehicle.

Clozapine exhibits a high afﬁnity for D4 receptors, as do many
other APDs including olanzapine, risperidone and haloperidol
(Bymaster et al. 1996; Roth et al. 1995). As noted previously, the
1.25 mg/kg dose of clozapine fully generalizes to all atypical APDs
tested so far, with the exception of quetiapine (Porter et al. 2000).
Quetiapine lacks an appreciable afﬁnity for D4 receptors, perhaps
accounting for partial substitution for clozapine in this previous
study. Yet, many typical APDs exhibit a high afﬁnity for D4 receptors, but do not include full or partial substitution. A potential
difference between atypical and typical APDs regarding D4 receptor binding is that many atypical APDs exhibit a greater afﬁnity
for D4 receptors over D2 receptors, whereas the vast majority of
typical APDs have a greater afﬁnity for D2 receptors than D4 receptors (Roth et al. 1995). This might explain a lack of full stimulus
generalization from a 1.25 mg/kg dose of clozapine to quetiapine,
but not account for full substitution for risperidone, which engenders a greater afﬁnity for D2 receptors than for D4 receptors
(Porter et al. 2000). Neither does a high afﬁnity for D4 and 5-HT2A
receptors appear to only explain substitution for clozapine by
atypical, but not typical, APDs (Porter et al. 2000), as many typical
APDs also exhibit a high to moderate afﬁnity for 5-HT2A receptors
(although typical APDs have a stronger afﬁnity for D2 receptors
compared to 5-HT2A receptors) (Roth et al. 1995). It may instead be
the case that antagonism of both D4 and 5-HT2A receptors produces clozapine-like discriminative stimulus effects, but that additional antagonism of D2 receptors with an afﬁnity greater than
5-HT2A receptors, makes these stimulus effects unlike clozapine.
Thus, drugs that also have a strong afﬁnity for D2 receptors do not
produce full stimulus generalization from clozapine.
Stimulus effects of higher training doses of CLZ in rats are
clearly mediated by muscarinic receptor antagonism, based on
substitution by muscarinic receptor antagonists atropine (Nielsen,
1988), scopolamine (Goudie et al. 1998; Kelley and Porter, 1997;
Nielsen 1988) and trihexyphenidyl (Kelley and Porter, 1997; Prus
et al. 2004). The present study did not ﬁnd partial or full substitution by either scopolamine or trihexyphenidyl. Prus et al.
(2006) also did not ﬁnd substitution for a 1.25 mg/kg training dose
of CLZ by scopolamine, while Prus et al. (2004) did ﬁnd full substitution for this training dose by trihexyphenidyl. Overall, a key
distinction between the discriminative stimulus effects of these
two training doses appears to be the prominence of muscarinic
antagonism with the higher training dose.
Stimulus properties elicited by muscarinic receptor antagonism
for the higher training dose of CLZ in rats, in turn, may overshadow the stimulus properties elicited by 5-HT2A or D4 receptors
found in the 1.25 mg/kg CLZ training dose. In rats trained to discriminate a 1.25 mg/kg dose of CLZ versus a 5.0 mg/kg dose of CLZ
versus vehicle, the primary difference between these stimuli
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consisted of partial substitution for a 5.0 mg/kg dose, but not a
1.25 mg/kg dose, with scopolamine (Prus et al. 2006). Further, in
this same study, partial substitution occurred for the 1.25 mg/kg
CLZ dose, but not the 5.0 mg/kg dose, with ritanserin. Comparatively, 5-HT2A receptor inverse agonism may elicit weaker stimulus
effects than muscarinic receptor antagonism. For example, Dekeyne et al. (2002) reported that training M100907 (0.16 mg/kg) as
a discriminative stimulus required approximately 70 sessions,
whereas Kelley and Porter (1997) reported that training scopolamine (0.125 mg/kg) as a discriminative stimulus required approximately 50 sessions.
While full stimulus generalization did not occur from CLZ to the
α1 adrenoceptor antagonist prazosin, the level of CLZ-appropriate
responding was over 60% (i.e., partial substitution), beyond
“chance level choice” in a two lever task. Goudie et al. (1998) also
reported a maximum of 67% substitution for a 5.0 mg/kg CLZ
training dose with prazosin in rats. α1 adrenoceptor antagonism is
another receptor mechanism shared by many, but not all, atypical
APDs as well as typical APDs (Schotte et al. 1996). In a study that
trained rats to discriminate the typical APD chlorpromazine from
5.0 mg/kg CLZ from vehicle in a three-choice drug discrimination
procedure in rats, prazosin produced full substitution for chlorpromazine, but not CLZ (Porter et al. 2005). Given these ﬁndings, it
does not appear that α1 adrenoceptor antagonism is unique to the
stimulus properties of either dose of CLZ in rats, nor does it appear
to generate stimulus effects unique to atypical APDs.
Beyond the data discussed so far, the remaining receptor ligands explored do not appear relevant to the stimulus properties
of a 1.25 mg/kg CLZ training dose in rats. Based on the present
ﬁndings, receptors lacking a role in this cue include D2 receptors,
H1 histamine receptors, benzodiazepine sites on GABAA receptors
(i.e., chlordiazepoxide), and 5-HT6 receptors. It is worth noting
that not all compounds failing to produce at least partial substitution were tested up to rate-suppressant doses, although a
wide range of doses was tested for each compound. Differences in
the mediation of the discriminative stimulus properties of CLZ do
occur between species, however. In male C57/BL mice, full substitution for CLZ with ritanserin (Philibin et al. 2005) and M100907
(Philibin et al. 2009) has been reported, and the discriminative
stimulus effects of CLZ have been blocked by pretreatment with
the 5-HT agonist quipazine (Philibin et al. 2005). These data suggest that 5-HT2A receptor antagonism mediates the discriminative
stimulus properties of CLZ in mice. In pigeons, 5-HT2 receptors also
exhibit CLZ-like stimulus effects (Hoenicke et al. 1992). Despite the
apparent greater prominence of 5-HT mediated stimulus effects
for CLZ in mice or pigeons, which would be more representative of
what is thought to be highly important for atypicality, the CLZ
discriminative stimulus in mice does not adequately screen atypical from typical APDs (Philibin et al. 2009) and most atypical
APDs have yet to be tested in pigeons (Hoenicke et al. 1992).
The present study explored the discriminative stimulus properties of the prototypical atypical APD CLZ in rats, using a 1.25 mg/
kg training dose of clozapine with has effectively screened typical
from atypical APDs in past studies. Thus, this training dose in the
drug discrimination paradigm appears to have utility as a
screening model in APD development. There appears to be a basis
for 5-HT2A receptors, which would ﬁt with currently established
models for atypicality. Moreover, D4 receptor antagonism also
appears to mediate the discriminative stimulus properties of CLZ,
especially when antagonism of both 5-HT2A and D4 receptors occur. Such models would be important as CLZ, despite being discovered well over half a century ago, remains one of the most, if
not the most, effective atypical APDs available for clinical use.
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4. Experimental procedure
4.1. Subjects
Experiments were conducted in 56 male Sprague Dawley rats
(Harlan, Indianapolis, IN) with new cohorts of rats added over
time. All rats were individually housed under constant temperature and humidity conditions and a 12 h light/dark cycle. Rats all
weighed over 300 g prior to any experimental procedures taking
place. The rats were food restricted to maintain 85% of free-feeding weights, but free-access to water was provided in the home
cages. All procedures were approved by the Institutional Animal
Care and Use Committee at Virginia Commonwealth University
and followed the Guide for the Care and Use of Laboratory Animals
(National Research Council Committee for the Update of the Guide
for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, National Academies Press, 2011).
4.2. Apparatus
All drug discrimination sessions were conducted in four standard computer-operated two lever (retractable) rat operant
chambers equipped with food pellet delivery and housed in
sound-attenuating cubicles with fans installed for ventilation and
masking noise (Med Associates, St. Albans, VT). Experimental
events were controlled by and data were collected using Med-PC
version 3.0 (Med-Associates). A light near the top of each chamber
provided illumination during all experimental sessions. Food reinforcers consisted of 45 mg powderless food pellets (Noyes Precision Pellets, Formula P, Research Diets, Inc., New Brunswick, NJ).
4.3. Drugs
The following drugs were administered: the atypical APD CLZ
(gift from Novartis Pharmaceutical Corporation, East Hanover, NJ),
the typical APD haloperidol (Sigma Chemical Company, St. Louis,
MO), the psychostimulant D-amphetamine (Sigma-Aldrich, St.
Louis, MO), the anxiolytic chlordiazepoxide (Sigma-Aldrich), the
dopamine D4 receptor antagonist Lu 38-012 (Hertel et al. 2007)
(Lundbeck, Copenhagen-Valby, Denmark), the muscarinic receptor
antagonist scopolamine (Sigma-Aldrich), the M1 receptor preferring antagonist trihexyphenidyl (Sigma-Aldrich), the serotonin
(5-HT)2A/2B/2C receptor antagonist ritanserin (Research Biochemical International, Natick, MA), the 5-HT2A receptor inverse agonist
M100907 (Sigma-Aldrich), the 5-HT2C receptor antagonist ORG
38,457 (Tocris), the 5-HT6 receptor antagonist RO-8554 (gift from
Roche Pharmaceuticals, Palo Alto, CA), the 5-HT6 receptor antagonist SB 271,046 (Tocris), the 5-HT7 receptor partial inverse
agonist SB 258,741 (Tocris), the α1 adrenoceptor antagonist prazosin (Research Biochemical International), the histamine H1 receptor antagonist pyrilamine (Research Biochemical International),
the D4 receptor antagonist and 5-HT reuptake inhibitor Lu 35-138
(Bang-Andersen et al. 2007; Hertel et al. 2007) (Lundbeck), the
preferential D4/5-HT2/α1 receptor antagonists 1-(3-(4-(1H-indol5-yl)piperazin-1-yl)propyl)  3,4-dihydroquinolin-2(1H)-one
(Bang-Andersen et al. 2002) (Lu 37-254) (Lundbeck) and (S)-1-(3(2-(4-(1H-indol-5-yl)piperazin-1-yl)ethyl)indolin-1-yl)ethan-1one (Lu 37-114 (Bang-Andersen et al. 2007) (Lundbeck). All drugs
were dissolved in CLZ vehicle (de-ionized H2O with 1-2 drops of
lactic acid), except for the Lundbeck compounds, which were
dissolved in a 10% 2-hydroxypropyl-β-cyclodextrin solution. All
drugs were administered intraperitoneally at a volume 1 ml/kg
body weight. Doses of scopolamine (HCl), SB 271,046 (HCl), prazosin (HCl), pyrilamine (maleate), Lu 37-114 (HCl), Lu 35-138 (HCl)
and Lu 37-254 (HCl) doses were in the salt form, and doses for all
other compounds refer to the base form. CLZ and RO-8554 were
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administered one hour prior to session and all other drugs were
administered 30 min prior to session. Injection routes, pre-injection times, and doses for these drugs were based on previous
studies in this laboratory and at Lundbeck.

analysis of variance (ANOVA) was conducted to assess differences
in response rates for a drug across doses, and for statistically signiﬁcant F values, Newman-Keuls post hoc multiple comparison
tests were conducted to identify rate-suppressant doses relative to
vehicle control.

4.4. Binding and functional assays
Binding assays at the dopamine D2 and D4.2 receptors, the
5-HT2 and 5-HT2C receptors, and α1 adrenergic receptors for Lu 37254 and Lu 37-114 were performed as described previously (Balle
et al. 2003). Additionally, the 5-HT uptake functional assay was
performed as described in Hertel et al. (2007).
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4.5. Behavioral procedures
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